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Hepatocellular Carcinoma (HCC) is one of the most common malig-
nant tumor, which is causing the second leading cancer-related death
worldwide. The tumor tissues and the adjacent noncancerous tissues
obtained from HCC patients with single and multiple lesions were
quantiﬁed using iTRAQ. A total of 5513 proteins (FDR of 1%) were
identiﬁed which correspond to roughly 27% of the total liver proteome.
And 107 and 330 proteins were dysregulated in HCC tissue with
multiple lesions (MC group) and HCC tissue with a single lesion (SC
group), compared with their noncancerous tissue (MN and SN group)
respectively. Bioinformatics analysis (GO, KEGG and IPA) allowed these
data to be organized into distinct categories. The data accompanying
the manuscript on this approach (Xing et al., J. Proteomics (2015),
http://dx.doi.org/10.1016/j.jprot.2015.08.007 [1]) have been deposited
to the iProX with identiﬁer IPX00037601.
& 2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.jprot.2015.08.007
Province, Fujian Medical University, Fuzhou 350025, People’s Republic of
).
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ject areaProteomics on the Hepatocellular Carcinomaype of data List of identiﬁed proteins as tables (.xls), raw data in website
ow data was
acquiredThe data was acquired by Liquid chromatography mass spectrometry in
tandem (LC–MS/MS).The samples were separated by a Acquity UPLC system
(Waters Corporation, Milford, MA) and detected by a Nano-Aquity UPLC
system (Waters Corporation, Milford, MA) connected to a quadrupole-
Orbitrap mass spectrometer (Q-Exactive) (Thermo Fisher Scientiﬁc, Bremen,
Germany).ata format Filtered and analyzed
xperimental
factorsNon-appliedxperimental
featuresProteins were extracted from tumor tissues of HCC patients with single and
multiple lesions, iTRAQ labeled and then prepared for liquid
chromatography-mass spectrometry (LC–MS/MS) analysis.ata source
locationFuzhou, China, Mengchao Hepatobiliary Hospital of Fujian Medical
Universityata accessibility Filtered and analyzed data are supplied here and raw data have also been
deposited to the integrated Proteome resources (iProX) with identiﬁer
IPX00037601 (http://www.iprox.org/index).roteome dataset. (A) Frequency distribution of the identiﬁed proteins with Z1 unique peptides.
ibution of identiﬁed proteins proved that there is no bias in the protein extraction process.
tion of the identiﬁed proteins to show the unbias of the protein extraction. (D) Protein hydro-
identiﬁed proteins.
X. Xing et al. / Data in Brief 5 (2015) 226–240228Value of the data The proteome of hepatocellular carcinoma with single and multiple lesions analyzed using
iTRAQ technology.
 A total of 5513 proteins (FDR of 1%) were identiﬁed which correspond to roughly 27% of the total
liver proteome.
 The in-depth proteomics analysis of the HCC tumor tissues with a single and multiple lesions might
be useful for further study of the mechanisms.Fig. 2. The iTRAQ ratio distribution and involved biological processes of the differentially expressed proteins in the HCC with
single and multiple lesions. (A) Volcano plot represented the protein abundance changes in the HCC cancerous tissue with
multiple lesions comparing to their adjacent noncancerous tissues. A total of 107 dysregulated proteins with fold change Z1.5
and p values o0.05 were identiﬁed. (B) Volcano plot represented the protein abundance changes in the HCC cancerous tissues
with a single lesion comparing to their adjacent noncancerous tissue. A total of 330 dysregulated proteins with fold change
Z1.5 and p values o0.05 were identiﬁed. (C) Venn diagrams showed the overlaps and number of differentially expressed
proteins in the HCC with single and multiple lesions. (D) GO analysis of the involved biological processes of the common
dysregulated proteins in both types of the HCC. All of the biological processes were ranked in term of enrichment of the
differentially expressed proteins, and the top 10 are presented here.
Table 1
Basic information and characteristics of the HCC patients with a single or multiple observed lesions, who were enrolled in this
dataset.
　 HCC with multiple
lesions
HCC with a single
lesion
Gender
Male 30 30
Female 0 0
Age (years)
r55 17 17
455 13 13
AFP (ng/ml)
r400 12 20
4400 18 10
Tumor size (cm)
r5 9 6
5–10 21 24
Progression of cirrhosis
None 3 5
Mild 13 12
Moderate 13 12
Severe 1 1
Tumor boundaries
Distinct 18 22
Indistinct 12 8
Differentiation degree
I–II 8 4
II–III 17 22
III–IV 5 4
Vascular tumor thrombosis
No 26 25
Yes 4 5
Tumor encapsulation
No 2 6
Incomplete 14 10
Complete 14 14
X. Xing et al. / Data in Brief 5 (2015) 226–240 2291. Data, experimental design, materials and methods
1.1. Data and experimental design
The data show the lists of proteins identiﬁed and quantiﬁed in the HCC tumor tissues with single and
multiple lesions. The tissues were divided into 4 groups: cancerous tissues from HCC patients with
multiple observed lesions (MC group, n¼30); surrounding noncancerous tissues from HCC patients with
multiple observed lesions (MN group, n¼30); cancerous tissues from primary HCC patients with a single
observed lesion (SC group, n¼30); surrounding noncancerous tissues from primary HCC patients with a
single observed lesion (SN group, n¼30). The detailed characteristics of the selected HCC patients were
listed in Table 1. For each group, every 5 individual samples with equal tissue weight were mixed, and then
the proteins were extracted from the mixed samples. And then the samples were labeled with the iTRAQ
Fig. 3. The hierarchical clustering and involved biological processes analysis of differentially expressed proteins in the primary
HCC with single and multiple lesions. (A) Hierarchical clustering of the 107 dysregulated proteins in the HCC with multiple
lesions (MC vs. MN). (B) Hierarchical clustering of the 330 dysregulated proteins in the HCC with a single lesion (SC vs. SN). (C,
D) GO analysis of the dysregulated proteins involved biological processes in the HCC with multiple lesions (C) and in the HCC
with a single lesion (D).
X. Xing et al. / Data in Brief 5 (2015) 226–2402308-plex reagent as follows: four groups (MC group, MN group, SC group and SN group) were labeled with
113, 114, 115 and 116 isobaric tag, respectively; and the peptides from the biological repetitions of the
above 4 groups were labeled with 117, 118, 119 and 121, respectively. The iTRAQ 8-plex labeling was
independently repeated 3 times, deﬁning as A, B and C. So we have 6 repeated protein extracts for each
group to minimize the individual differences of the patients.
1.2. Materials and methods
Tissue samples, including the cancerous and surrounding noncancerous tissues, were obtained from 30
primary HCC patients with multiple observed lesions and 30 primary HCC patients with a single observed
lesion, respectively. All patients have undergone radical surgery at Mengchao Hepatobiliary Hospital of
Fujian Medical University from August 2010 to January 2013. The protein from these two type HCC tissues
was determined by BCA assay (TransGen Biotech, Beijing, China) following the manufacture’s protocol.
Afterwards, 100 μg proteins per condition were treated with DTT (8 mM) and iodoacetamide (50 mM) for
reduction and alkylation. Afterwards, the proteins were typically digested by sequence-grade modiﬁed
trypsin (Promega, Madison, WI), and then the resultant peptides mixture was further labeled using che-
micals from the iTRAQ reagent kit (AB SCIEX, USA).
The peptide mixture was fractionated by high pH separation using a Acquity UPLC system (Waters
Corporation, Milford, MA) connected to a reverse phase column (BEH C18, 1.7 mm, 2.150 mm2, Waters
Corporation, Milford, MA). High pH separationwas performed using a linear gradient starting from 5% B to
35% B in 20min (solution B: 20 mM ammonium formate in 90% ACN, the pH was adjusted to 10.0 with
ammonium hydroxide). The column ﬂow rate was maintained at 600 μl/min and column temperature was
Table 2
List of the differentially expressed proteins which is only dysregulated in HCC with multiple lesions.
Differentially expressed proteins Gene Fold
change
Fold
change
MC/MN SC/SN
UTP-glucose-1-phosphate
uridylyltransferase
UGP2 0.62 0.68
Bile acyl-CoA synthetase SLC27A5 0.58 0.67
Cytochrome P450 2A6 CYP2A6 0.6 0.73
Glycine dehydrogenase (decarboxylating),
mitochondrial
GLDC 0.65 0.72
17-Beta-hydroxysteroid dehydrogenase
13
HSD17B13 0.56 0.71
Glycogen [starch] synthase, liver GYS2 0.65 0.7
Sequestome-1 SQSTM1 1.77 1.59
4-Hydroxyphenylpyruvate dioxygenase HPD 0.63 0.76
Kynurenine 3-monooxygenase KMO 0.56 0.76
Beta-enolase ENO3 0.64 0.71
Urocanate hydratase UROC1 0.66 0.76
Keratin, type I cytkeletal 20 KRT20 1.53 1.97
Synembryn-A RIC8A 1.56 1.4
Cadherin-related family member 2 CDHR2 0.64 0.78
Cytochrome P450 2B6 CYP2B6 0.64 0.69
NAD(P)H dehydrogenase [quinone] 1 NQO1 1.89 1.52
Anterior gradient protein 2 homolog AGR2 1.71 1.14
Peripherin PRPH 0.64 0.7
Fuce mutarotase FUOM 0.6 0.61
Coiled-coil domain-containing protein 57 CCDC57 1.54 1.4
Gangliide-induced differentiation-asso-
ciated protein 1
GDAP1 1.51 1.44
Histone H1.1 HIST1H1A 1.62 1.12
Choline transporter-like protein 2 SLC44A2 0.65 0.63
RAS protein activator like-3 RASAL3 0.63 0.79
Non-histone chromomal protein HMG-17 HMGN2 3.06 1.65
FH1/FH2 domain-containing protein 1 FHOD1 1.66 1.44
Copine-6 CPNE6 0.58 0.78
Myeloblastin PRTN3 1.51 1.94
24-Hydroxycholesterol 7-alpha-
hydroxylase
CYP39A1 0.61 0.71
Sodium/hydrogen exchanger 10 SLC9C1 0.63 0.68
Steroid 17-alpha-hydroxylase/17,20 lyase CYP17A1 1.57 2.15
HLA class I histocompatibility antigen,
alpha chain G
HLA-G 0.66 1.08
MICAL C-terminal-like protein MICALCL 0.49 0.4
Nucleolysin TIA-1 isoform p40 TIA1 0.66 0.91
Immunoglobulin-binding protein 1 IGBP1 1.57 1.63
Protein FAM171A1 FAM171A1 0.59 0.63
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interval were pooled together to reduce the fraction numbers, such as 1 and 21, 2 and 22, and so on [2].
Twenty fractions at the end were dried in a vacuum concentrator for further usage.
The fractions were then separated by nano-LC and analyzed by on-line electrospray tandem mass
spectrometry. The experiments were performed on a Nano-Aquity UPLC system (Waters Corporation,
Milford, MA) connected to a quadrupole-Orbitrap mass spectrometer (Q-Exactive) (Thermo Fisher
Scientiﬁc, Bremen, Germany) equipped with an online nano-electrospray ion source. 8 μl peptide
sample was loaded onto the trap column (Thermo Scientiﬁc Acclaim PepMap C18, 100 μm2 cm)
with a ﬂow of 10 μl/min, and subsequently separated on the analytical column (Acclaim PepMap C18,
75 μm50 cm) with a linear gradient, from 2% D to 40% D in 135 min (solution D: 0.1% formic acid in
Table 3
List of the differentially expressed proteins which is only dysregulated in HCC with a single lesion.
Differentially expressed proteins Gene Fold
change
Fold
change
MC/MN SC/SN
Keratin, type II cytkeletal 8 KRT8 0.73 0.62
Keratin, type I cytkeletal 18 KRT18 0.72 0.6
Tenascin-X TNXB 0.72 0.65
C-1-tetrahydrofolate synthase, cytoplasmic MTHFD1 0.72 0.56
Trifunctional enzyme subunit beta,
mitochondrial
HADHB 0.91 0.6
Acetyl-CoA acetyltransferase, mitochondrial ACAT1 0.78 0.61
Long-chain-fatty-acid–CoA ligase 1 ACSL1 0.72 0.65
Haptoglobin HP 0.68 0.5
3-Ketoacyl-CoA thiolase, mitochondrial ACAA2 0.81 0.5
Non-speciﬁc lipid-transfer protein SCP2 0.91 0.65
Lumican LUM 0.86 0.63
Fatty acid-binding protein, liver FABP1 0.68 0.6
D-Beta-hydroxybutyrate dehydrogenase,
mitochondrial
BDH1 0.69 0.65
Betaine–homocysteine S-methyltransferase 1 BHMT 0.67 0.58
Putative hexokinase HKDC1 HKDC1 1.28 1.54
L-Lactate dehydrogenase A chain LDHA 1.24 1.6
Pyruvate kinase PKM PKM 1.25 1.59
X-ray repair crs-complementing protein 6 XRCC6 1.36 1.63
Enoyl-CoA hydratase, mitochondrial ECHS1 0.86 0.55
Delta(3,5)-Delta(2,4)-dienoyl-CoA iso-
merase, mitochondrial
ECH1 0.87 0.65
ATP synthase subunit d, mitochondrial ATP5H 0.78 0.56
Laminin subunit beta-1 LAMB1 1.42 1.53
S-adenylmethionine synthase isoform type-1 MAT1A 0.74 0.66
X-ray repair crs-complementing protein 5 XRCC5 1.49 1.77
Electron transfer ﬂavoprotein subunit alpha,
mitochondrial
ETFA 0.83 0.65
ATP-citrate synthase ACLY 1.16 1.7
Myeloperoxidase MPO 1.37 1.58
Glucose-6-phosphate isomerase GPI 1.14 1.83
Villin-1 VIL1 1.36 1.75
Short/branched chain speciﬁc acyl-CoA
dehydrogenase, mitochondrial
ACADSB 0.86 0.61
Endoplasmic reticulum resident protein 29 ERP29 0.77 0.59
Superoxide dismutase [Cu–Zn] SOD1 0.83 0.64
C4b-binding protein alpha chain C4BPA 1.24 1.62
DnaJ homolog subfamily B member 9 DNAJB9 0.81 0.45
3-Ketoacyl-CoA thiolase, peroxisomal ACAA1 0.8 0.63
Decorin DCN 0.8 0.64
Transketolase TKT 1.42 1.66
Ferritin light chain FTL 0.73 0.62
Elongation factor 1-gamma EEF1G 1.18 1.55
Cytochrome b-c1 complex subunit 7 UQCRB 0.79 0.53
Transferrin receptor protein 1 TFRC 1.49 1.89
Glycerol-3-phosphate dehydrogenase [NAD
(þ)], cytoplasmic
GPD1 0.77 0.64
Peroxiredoxin-4 PRDX4 0.7 0.64
Mimecan OGN 0.77 0.62
Cytochrome c oxidase subunit 6B1 COX6B1 0.79 0.58
NADH dehydrogenase [ubiquinone] ﬂavo-
protein 2, mitochondrial
NDUFV2 0.82 0.55
Phenylalanine-4-hydroxylase PAH 0.68 0.66
6-Phosphogluconate dehydrogenase,
decarboxylating
PGD 1.22 1.73
ATP synthase subunit O, mitochondrial ATP5O 0.93 0.66
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Table 3 (continued )
Differentially expressed proteins Gene Fold
change
Fold
change
MC/MN SC/SN
Cytochrome b-c1 complex subunit Rieske,
mitochondrial
UQCRFS1 0.85 0.65
Cytochrome c oxidase subunit 5B,
mitochondrial
COX5B 0.79 0.55
Dehydrogenase/reductase SDR family
member 4
DHRS4 0.94 0.6
Gamma-glutamyltransferase 5 GGT5 0.67 0.6
Sulfotransferase 1A1 SULT1A1 0.81 0.58
Carboxypeptidase D CPD 1.44 1.61
Spliceome RNA helicase DDX39B DDX39B 1.18 1.53
Core histone macro-H2A.1 H2AFY 1.48 1.51
Polymerase I and transcript release factor PTRF 0.83 0.62
Apolipoprotein D APOD 0.84 0.66
ATP synthase-coupling factor 6,
mitochondrial
ATP5J 0.78 0.56
Glucose-6-phosphate 1-dehydrogenase G6PD 1.43 1.61
2-Oxoisovalerate dehydrogenase subunit
alpha, mitochondrial
BCKDHA 0.83 0.63
NADH dehydrogenase [ubiquinone] 1 beta
subcomplex subunit 10
NDUFB10 0.83 0.58
Glycine N-acyltransferase GLYAT 0.73 0.6
Cytochrome c oxidase subunit 5A,
mitochondrial
COX5A 0.82 0.59
DNA replication licensing factor MCM3 MCM3 1.5 1.62
Ribonuclease UK114 HRSP12 0.82 0.65
Phenazine biosynthesis-like domain-con-
taining protein
PBLD 0.72 0.58
Asparagine–tRNA ligase, cytoplasmic NARS 1.43 1.67
Lamin-B receptor LBR 1.36 1.68
Polypeptide N-acetylgalactaminyltransfer-
ase 2
GALNT2 1.22 1.58
Paralemmin-3 PALM3 0.71 0.63
EGF-containing ﬁbulin-like extracellular
matrix protein 1
EFEMP1 1.37 1.51
Heme-binding protein 1 HEBP1 0.83 0.54
Apolipoprotein C-III APOC3 0.92 0.66
Phosphoglucomutase-2 PGM2 1.16 1.85
Complement factor H-related protein 5 CFHR5 0.89 0.63
L-Lactate dehydrogenase B chain LDHB 1.2 1.62
Serine–tRNA ligase, cytoplasmic SARS 1.09 1.55
ATP synthase subunit e, mitochondrial ATP5I 0.79 0.56
Creatine kinase B-type CKB 0.95 1.92
NADH dehydrogenase [ubiquinone] 1 alpha
subcomplex subunit 5
NDUFA5 0.74 0.53
NADH dehydrogenase [ubiquinone] iron–
sulfur protein 8, mitochondrial
NDUFS8 0.89 0.66
Desmin DES 0.71 0.51
DNA replication licensing factor MCM6 MCM6 1.34 1.54
Serum deprivation-response protein SDPR 0.79 0.55
Acyl-coenzyme A synthetase ACSM3,
mitochondrial
ACSM3 0.75 0.6
Clathrin light chain B CLTB 0.88 0.65
Probable D-lactate dehydrogenase,
mitochondrial
LDHD 0.75 0.63
Beta-2-microglobulin B2M 0.87 0.63
Four and a half LIM domains protein 1 FHL1 0.86 0.66
NADH dehydrogenase [ubiquinone] 1 alpha
subcomplex subunit 2
NDUFA2 0.85 0.58
Perilipin-2 PLIN2 1.23 1.65
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Table 3 (continued )
Differentially expressed proteins Gene Fold
change
Fold
change
MC/MN SC/SN
NADH dehydrogenase [ubiquinone] 1 alpha
subcomplex subunit 8
NDUFA8 0.72 0.47
Tubulointerstitial nephritis antigen-like TINAGL1 0.81 0.61
Farnesyl pyrophosphate synthase FDPS 1.37 1.6
Minor histocompatibility antigen H13 HM13 1.3 1.68
Glutathione peroxidase 1 GPX1 0.81 0.64
DNA-(apurinic or apyrimidinic site) lyase AX1 1.34 1.67
Procollagen-lysine, 2-oxoglutarate 5-dioxy-
genase 3
PLOD3 1.15 1.58
Angiotensinogen AGT 1.14 1.55
Transmembrane protein 2 TMEM2 1.1 1.51
Alpha/beta hydrolase domain-containing
protein 14B
ABHD14B 0.86 0.66
EF-hand domain-containing protein D1 EFHD1 0.81 0.65
Protein mago nashi homolog 2 MAGOHB 1.3 1.73
3-Hydroxyanthranilate 3,4-dioxygenase HAAO 0.79 0.66
Coﬁlin-2 CFL2 0.78 0.64
NADH dehydrogenase [ubiquinone] iron–
sulfur protein 6, mitochondrial
NDUFS6 0.82 0.47
NADH dehydrogenase [ubiquinone] 1 alpha
subcomplex subunit 12
NDUFA12 0.8 0.62
Alpha-fetoprotein AFP 1.02 2.13
Proliferating cell nuclear antigen PCNA 1.43 1.62
Transmembrane 9 superfamily member 4 TM9SF4 1.35 1.54
NADH dehydrogenase [ubiquinone] iron–
sulfur protein 5
NDUFS5 0.82 0.56
Nuclear cap-binding protein subunit 1 NCBP1 1.34 1.55
Dermatopontin DPT 0.74 0.62
Glycine N-methyltransferase GNMT 0.8 0.65
Ataxin-10 ATXN10 1.38 1.57
UPF0553 protein C9orf64 C9orf64 1.41 1.64
BRO1 domain-containing protein BROX BROX 1.38 1.51
NADH dehydrogenase [ubiquinone] iron–
sulfur protein 4, mitochondrial
NDUFS4 0.78 0.5
L-Serine dehydratase/L-threonine
deaminase
SDS 1.01 0.65
Protein transport protein Sec23B SEC23B 1.39 1.65
Mitochondrial import inner membrane
translocase subunit Tim8 A
TIMM8A 0.82 0.56
Nicastrin NCSTN 1.29 1.53
Cytochrome P450 3A7 CYP3A7 1.38 1.94
40S ribomal protein S15 RPS15 1.08 0.55
Integrin alpha-IIb ITGA2B 1.1 0.65
Acyl-CoA:lysophosphatidylglycerol acyl-
transferase 1
LPGAT1 1.14 1.51
Apolipoprotein L1 APOL1 1.36 1.61
Peptidyl-prolyl cis–trans isomerase FKBP2 FKBP2 0.9 0.66
Complement factor H-related protein 1 CFHR1 0.7 0.63
Plasma serine protease inhibitor SERPINA5 1.08 1.52
Mitochondrial import inner membrane
translocase subunit Tim13
TIMM13 0.81 0.48
Tropomodulin-1 TMOD1 0.83 0.64
Myin regulatory light polypeptide 9 MYL9 0.82 0.62
ER lumen protein retaining receptor 1 KDELR1 1.1 1.58
NAD-dependent malic enzyme,
mitochondrial
ME2 1.33 1.6
Ceramide synthase 2 CERS2 1.47 1.51
Monocarboxylate transporter 4 SLC16A3 1.44 1.66
Glutaredoxin-1 GLRX 0.82 0.66
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Table 3 (continued )
Differentially expressed proteins Gene Fold
change
Fold
change
MC/MN SC/SN
Collagen alpha-6(VI) chain COL6A6 0.75 0.63
Group XIIB secretory phospholipase A2-like
protein
PLA2G12B 0.79 0.59
Latent-transforming growth factor beta-
binding protein 2
LTBP2 1.33 1.53
Myin-7 MYH7 1.14 2.46
15 kDa selenoprotein 15-Sep 0.69 0.58
Metalloproteinase inhibitor 1 TIMP1 1.33 1.52
Protein RCC2 RCC2 1.37 1.65
NADH dehydrogenase [ubiquinone] 1 alpha
subcomplex subunit 7
NDUFA7 0.86 0.57
Calmegin CLGN 1.41 1.75
Apolipoprotein(a) LPA 0.74 0.64
Elongation factor 1-alpha 2 EEF1A2 1.13 1.74
Cytochrome c oxidase protein 20 homolog COX20 1.38 1.63
Translin TSN 1.2 1.57
Folate receptor beta FOLR2 0.72 0.65
Secretory carrier-associated membrane
protein 3
SCAMP3 1.38 1.53
Chitinase-3-like protein 1 CHI3L1 1.11 1.86
Mitochondrial intermembrane space import
and assembly protein 40
CHCHD4 0.9 0.57
Fibrocystin-L PKHD1L1 0.71 0.55
Girdin CCDC88A 0.82 0.38
Flap endonuclease 1 FEN1 1.3 1.74
Solute carrier family 43 member 3 SLC43A3 1.29 1.65
Complement factor H-related protein 3 CFHR3 0.84 0.59
Cleavage stimulation factor subunit 3 CSTF3 1.39 1.88
Protein kinase C delta-binding protein PRKCDBP 0.76 0.54
Transmembrane protein 176B TMEM176B 1.32 1.62
60 kDa lysophospholipase ASPG 0.7 0.62
Spermidine synthase SRM 1.2 1.51
B-cell receptor-associated protein 29 BCAP29 1.11 1.56
Retinol dehydrogenase 10 RDH10 1.36 1.58
PDZ and LIM domain protein 2 PDLIM2 0.8 0.6
Sodium/potassium-transporting ATPase
subunit beta-3
ATP1B3 1.46 1.56
Uncharacterized protein C19orf52 C19orf52 1.36 1.53
Transmembrane protein 70, mitochondrial TMEM70 1.24 1.51
Insulin-like growth factor 2 mRNA-binding
protein 2
IGF2BP2 1.41 1.77
C-reactive protein CRP 1.2 1.83
Importin subunit alpha-1 KPNA2 1.33 2.77
COX assembly mitochondrial protein
2 homolog
CMC2 0.82 0.61
Retinoic acid receptor responder protein 2 RARRES2 1.38 1.54
Oncoprotein-induced transcript 3 protein OIT3 0.71 0.59
Ficolin-1 FCN1 0.9 0.65
StAR-related lipid transfer protein 5 STARD5 0.76 0.56
Transmembrane protein 14C TMEM14C 1.33 1.64
P2X purinoceptor 4 P2RX4 1.39 1.58
Bifunctional lysine-speciﬁc demethylase
and histidyl-hydroxylase MINA
MINA 1.28 1.63
Myeloid leukemia factor 2 MLF2 0.81 0.58
C4b-binding protein beta chain C4BPB 1.16 1.65
Astrocytic phosphoprotein PEA-15 A15 1.07 1.53
Pituitary tumor-transforming gene 1 pro-
tein-interacting protein
PTTG1IP 1.36 1.68
Unconventional myin-XIX MYO19 1.4 1.55
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Table 3 (continued )
Differentially expressed proteins Gene Fold
change
Fold
change
MC/MN SC/SN
Ras-related protein Rab-3D RAB3D 1.49 1.61
F-box only protein 22 FBXO22 1.15 1.61
UPF0364 protein C6orf211 C6orf211 1.33 1.59
PRA1 family protein 2 PRAF2 1.28 1.53
Serine incorporator 1 SERINC1 1.41 1.53
Spermatogenesis-defective protein 39
homolog
VIPAS39 1.33 1.53
Ryanodine receptor 1 RYR1 0.91 1.52
AP-1 complex subunit gamma-like 2 AP1G2 1.4 1.65
Hexokinase-2 HK2 1.37 1.97
Uncharacterized protein C2orf42 C2orf42 1.19 1.53
Phospholipid transfer protein PLTP 1.05 2.05
PC4 and SFRS1-interacting protein PSIP1 1.3 1.53
Rho guanine nucleotide exchange factor 18 ARHGEF18 1.48 1.56
Acylphosphatase-2 ACYP2 0.82 0.6
Claudin-1 CLDN1 1.05 1.68
Neutral amino acid transporter B(0) SLC1A5 1.2 2
CB1 cannabinoid receptor-interacting pro-
tein 1
CNRIP1 0.91 0.66
Cytolic Fe–S cluster assembly factor NUBP2 NUBP2 0.84 0.6
Sortilin SORT1 1.12 1.51
UPF0729 protein C18orf32 C18orf32 1.15 1.77
Protein YIPF4 YIPF4 1.33 1.6
Cell growth regulator with EF hand domain
protein 1
CGREF1 1.11 1.54
Presenilins-associated rhomboid-like pro-
tein, mitochondrial
PARL 1.3 1.59
Bactericidal permeability-increasing protein BPI 1.23 1.66
Protein S100-A1 S100A1 1.27 1.63
Ammonium transporter Rh type A RHAG 2.34 1.83
Pleckstrin homology domain-containing
family G member 3
PLEKHG3 1.37 1.52
Putative methyltransferase NSUN5 NSUN5 0.71 0.59
Secretory carrier-associated membrane
protein 4
SCAMP4 1.32 1.61
Cochlin COCH 1.31 2.12
tRNA (guanine(10)-N2)-methyltransferase
homolog
TRMT11 1.33 2
Protein YIPF3 YIPF3 1.27 1.54
Synaptogyrin-1 SYNGR1 1.34 1.73
Ubiquitin carboxyl-terminal hydrolase iso-
zyme L1
UCHL1 1.26 1.57
MAP kinase-activated protein kinase 2 MAPKAPK2 1.41 1.52
Proteoglycan 3 PRG3 0.69 0.65
Bcl-2 homologous antagonist/killer BAK1 1.3 1.7
TNF receptor-associated factor 6 TRAF6 1.03 0.66
Ethanolamine-phosphate phospho-lyase ETNPPL 0.66 0.46
Proto-oncogene tyrine-protein kinase Src SRC 1.29 1.62
Folate transporter 1 SLC19A1 1.3 1.81
Platelet factor 4 PF4 0.76 0.54
Chloride intracellular channel protein 5 CLIC5 1 1.52
Negative elongation factor E NELFE 1.32 1.64
RNA polymerase II-associated protein 1 RPAP1 1.26 1.65
Zinc transporter SLC39A7 SLC39A7 1.67 2
Ankyrin repeat domain-containing protein
24
ANKRD24 0.8 1.65
Centromal protein of 85 kDa-like CEP85L 0.26 0.65
Caspase-3 CASP3 1.22 1.68
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Table 3 (continued )
Differentially expressed proteins Gene Fold
change
Fold
change
MC/MN SC/SN
Peroxisomal leader peptide-processing
protease
TYSND1 1.3 1.6
tRNA (guanine(37)-N1)-methyltransferase TRMT5 1.26 1.86
Mitochondrial inner membrane organizing
system protein 1
MINOS1 1.31 1.52
Coiled-coil domain-containing protein 153 CCDC153 1.36 2.47
Conserved oligomeric Golgi complex sub-
unit 8
COG8 1.23 1.56
Vesicle transport protein SFT2B SFT2D2 1.13 1.51
F-box only protein 10 FBXO10 0.71 0.63
Muskelin MKLN1 1.09 1.57
Tuftelin-interacting protein 11 TFIP11 1.27 1.52
Sulfotransferase 1C2 SULT1C2 1.15 1.62
Zinc transporter ZIP1 SLC39A1 1.45 1.91
Proton-coupled folate transporter SLC46A1 1.19 1.52
Putative heat shock protein HSP 90-beta 2 HSP90AB2P 1.29 2.25
Asparagine synthetase [glutamine-
hydrolyzing]
ASNS 1.21 2.7
Ubiquitin carboxyl-terminal hydrolase 38 USP38 0.64 0.52
Glycogen synthase kinase-3 alpha GSK3A 1.34 1.71
Coiled-coil domain-containing protein 69 CCDC69 0.8 0.66
Retinoid-binding protein 7 RBP7 0.95 1.51
Signal-transducing adaptor protein 2 STAP2 1.21 1.59
Soluble calcium-activated nucleotidase 1 CANT1 1.5 2
Threonine synthase-like 2 THNSL2 0.65 0.48
X. Xing et al. / Data in Brief 5 (2015) 226–240 237ACN). The Q-Exactive mass spectrometer was operated in the data-dependent mode to switch
automatically between MS and MS/MS acquisition. Survey full-scan MS spectra (m/z 350–1200) was
acquired with a mass resolution of 70 K, followed by 15 sequential high energy collisional dissociation
(HCD) MS/MS scans with a resolution of 17.5 K. In all cases, one microscan was recorded using
dynamic exclusion of 30 s.1.3. Data analysis
All the raw ﬁles generated by the Q-Exactive instrument were converted into mzXML and
MGF ﬁles using the ms convert module in Trans-Proteomic Pipeline (TPP 4.6.2). All MGF ﬁles were
searched using Mascot (Matrix Science, London, UK; version 2.3.0) against a human_database pro-
vided by The Universal Protein Resource (http://www.uniprot.org/uniprot, released at 2014-04-10,
with 20,264 entries). Using the results from Scaffold_4.3.2, we quantiﬁed 5513 proteins in three
iTRAQ 8-plex labeling replicates. The complete list of identiﬁed proteins in our dataset is shown in
Table S1. The detailed characteristics of proteomes of the primary HCC with single and multiple
lesions, including Molecular Weight (MW), Isoelectric Point (PI), Hydrophobicity, exponentially
modiﬁed Protein Abundance Index (emPAI), Quantitative Clustering, Average Coefﬁcient of Variance
(CV), quantiﬁcation results with percentage variability, were included in the list as well. The dis-
tribution of unique peptide numbers per protein, MW, PI and hydrophobicity also clearly showed that
the overall proteome datasets of the primary HCC with single and multiple lesions had no strong bias
(Fig. 1).
Fig. 4. Gene ontology (GO) function analysis of differentially expressed proteins which is only dysregulated in HCC with a
single lesion or HCC with multiple lesions. (A) GO analysis of the molecular function of the proteins which is only differentially
expressed in HCC with multiple lesions. (B) GO analysis of the molecular function of the proteins which is only differentially
expressed in HCC with a single lesion. (C) GO analysis of the cell component of the proteins which is only differentially
expressed in HCC with multiple lesions. (D) GO analysis of the cell component of the proteins which is only differentially
expressed in HCC with a single lesion. All of biological processes were ranked in term of the enrichment of the differentially
expressed proteins, and the top 10 are presented.
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2.1. The analysis of the quantitative proteomics
In this dataset, 107 and 330 proteins were classiﬁed as differentially expressed in HCC tumor
tissues with single and multiple lesions compared to surrounding noncancerous tissues (Fig. 2A, B).
All of the differentially expressed proteins presented a mean expression fold change of 71.5
(log2 0.58) or even more with a p value less than 0.05 (paired T-test), meanwhile these proteins
should have the same change trends in all six biological replicates. Among these differentially
expressed proteins, 71 proteins altered their expression in both HCC types (Fig. 2C). GO annotation
analysis showed that these proteins were the major participants in the oxidation reduction process
and the cellular metabolic processes (Fig. 2D).
Fig. 5. The key functions of the differentially expressed proteins involved in the HCC with single and multiple lesions according
to IPA analysis. (A) Enriched Functions of the differentially expressed proteins that is only dysregulated in HCC with multiple
lesions. (B) Enriched Functions of the differentially expressed proteins that is only dysregulated in HCC with a single lesion. All
of pathways were ranked in term of the enrichment of the differentially expressed proteins, and the top 10 were presented.
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The Gene Ontology (GO) annotation and pathway enrichment analysis of all the identiﬁed proteins
and differentially expressed proteins were implemented using the online tool DAVID (http://david.
abcc.ncifcrf.gov/). The quantitative iTRAQ ratios of 36 proteins, which dysregulated in MC group
comparing to MN group, but these proteins were not dysregulated in primary HCC with a single
lesion, were plotted on a heatmap (Fig. 3A). The names of the dysregulated proteins are listed in
Table 2. We further analyzed these protein involved biological process by GO analysis (Fig. 3C).
Meanwhile, 142 up-regulated proteins and 117 down-regulated proteins were speciﬁcally appeared in
HCC with a single lesion group, but not in HCC with multiple lesions group; and the up and down
regulated proteins also form clearly distinct clusters in the heatmap (Fig. 3B). The list of protein
names is also displayed in Table 3. We further analyzed these protein involved biological process by
GO analysis (Fig. 3D). Gene ontology (GO) analysis of the molecular function and cell component of
differentially expressed proteins which is only dysregulated in HCC with a single lesion or HCC with
multiple lesions are also displayed in Fig. 4.
The biological functions and signaling pathway annotations of the differentially expressed proteins
were analyzed by Ingenuity Pathways Analysis (IPA) software (version 7.5), which is based on the
Ingenuity Pathways database. The key functions of the differentially expressed proteins involved in
the HCC with single and multiple lesions according to IPA analysis are also displayed in Fig. 5. The GO
annotations, involved signaling pathways and networks were ranked in term of the enrichment of the
differentially expressed proteins.Acknowledgments
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